We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

GMAT3:BMFBOVESPAGrupo Mateus SA Analysis

Data as of 2026-03-17 - not real-time

R$5.02

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Grupo Mateus trades at R$5.02, roughly 26% above its DCF‑derived fair value of R$3.99, suggesting the stock is currently priced on the optimistic side. The valuation is further supported by a low trailing PE of 5.98 and a price‑to‑book of 1.11, but the bearish MACD (‑0.011 vs signal 0.068) and the fact that price sits below the 20‑day (5.44) and 50‑day (5.04) moving averages point to short‑term downside pressure. Revenue surged 29% YoY to R$36.6 bn, while margins remain modest (gross 22%, operating 6%). The dividend yield of 4.97% with a payout ratio under 30% appears sustainable given a free cash flow of R$387 m and a debt‑to‑equity of 57%. The company’s low leverage relative to peers and a stable volume trend further cushion liquidity concerns. However, Brazil’s consumer cyclical environment and currency fluctuations add medium‑level geographic and currency risk. With a beta of 0.45 and 30‑day volatility near 34%, the stock carries moderate market risk, but its solid cash generation and analyst consensus of “buy” (8 analysts) make it a compelling medium‑ to long‑term hold. Given the current upside potential of roughly 50% versus the DCF target, the stock offers a blend of value and growth characteristics.
Overall, the technical picture is neutral to slightly bearish in the short run, while the fundamentals and dividend profile support a buy stance for investors with a medium to long horizon.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD and price below short‑term SMAs
  • RSI near neutral at 40.9
  • Stable volume but no immediate catalyst

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong 29% revenue growth
  • Attractive dividend yield of 4.97% with low payout ratio
  • Low PE (5.98) and analyst consensus of "buy"

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Sustainable cash flow generation and manageable debt
  • Potential upside of ~50% versus DCF fair value
  • Blend of value (low multiples) and growth (revenue expansion)

Key Metrics & Analysis

Financial Health

Revenue Growth29.10%
Profit Margin5.16%
P/E Ratio6.0
ROE18.40%
ROA7.34%
Debt/Equity56.97
P/B Ratio1.1
Op. Cash FlowR$1.7B
Free Cash FlowR$387.0M

Technical Analysis

TrendNeutral
RSI40.9
SupportR$0.00
ResistanceR$5.99
MA 20R$5.44
MA 50R$5.04
MA 200R$6.31
MACDBearish
VolumeStable
Fear & Greed Index79.52

Valuation

Fair ValueR$3.99
Target PriceR$7.55
Upside/Downside50.40%
GradeOvervalued
TypeBlend
Dividend Yield4.97%

Risk Assessment

Beta0.45
Volatility33.86%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.